Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Fintel reports that on January 17, 2025, UBS downgraded their outlook for Charles River Laboratories International (NYSE:CRL) ...

UBS downgrades Charles River Laboratories (CRL) to neutral citing concerns about decelerating sales growth, lowers price target to $185. Read more here.

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

This was the stock's fourth consecutive day of losses.

A February meeting could bring about the end of the trade in macaque monkeys commonly used in medical research.